NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Oasmia Pharmaceutical AB ("Oasmia" or the "Company") (OASM) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Oasmia securities between October 23, 2015 through July 9, 2019, both dates inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
LOS ANGELES, CA / ACCESSWIRE / September 24, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Oasmia Pharmaceutical AB ("Oasmia" or "the Company") (NASDAQ:OASM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 23, 2015 and July 9, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 27, 2019.
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Oasmia securities between October 23, 2015 through July 9, 2019, both dates inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
Class-action law firm urges OASM investors to learn their shareholder rights against Oasmia in filed lawsuit SAN FRANCISCO , CA / ACCESSWIRE / September 24, 2019 / Hagens Berman reminds investors in Oasmia ...
Law Offices of Howard G. Smith reminds investors of the upcoming September 27, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM) securities between October 23, 2015 and July 9, 2019, inclusive (the “Class Period”). Investors suffering losses on their Oasmia investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Oasmia Pharmaceutical AB (“Oasmia” or “the Company”) (NASDAQ: OASM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Oasmia engaged in deceptive and improper related-party transactions with Alceco International S.A. and Ardenia Investment LTD. These improper transactions resulted in millions of Swedish Kronor not accounted for in the Company’s books.
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NEW YORK, Sept. 26, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Oasmia Pharmaceutical AB (NASDAQ: OASM) from October 23,.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 27, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM) investors who purchased securities between October 23, 2015 and July 9, 2019, inclusive (the “Class Period”). If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On June 28, 2019, the Company disclosed that it had reported certain suspicious transactions made between Oasmia and Alceco International S.A. (“Alceco”) and Ardenia Investments Ltd (“Ardenia”) to the Swedish Economic Crime Authority.
LOS ANGELES, CA / ACCESSWIRE / September 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Oasmia Pharmaceutical AB ("Oasmia" or "the Company") (NASDAQ:OASM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 23, 2015 and July 9, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 27, 2019.
LOS ANGELES, CA / ACCESSWIRE / September 25, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Oasmia Pharmaceutical AB ("Oasmia" or "the Company") (NASDAQ:OASM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 23, 2015 and July 9, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 27, 2019.
NEW YORK, NY / ACCESSWIRE / September 25, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Oasmia Pharmaceutical AB ("Oasmia" or the "Company") (OASM) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Oasmia securities between October 23, 2015 through July 9, 2019, both dates inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
Class-action law firm urges OASM investors to learn their shareholder rights against Oasmia in filed lawsuit SAN FRANCISCO, CA / ACCESSWIRE / September 26, 2019 / Hagens Berman reminds investors in Oasmia ...
Class-action law firm urges OASM investors to learn their shareholder rights against Oasmia in filed lawsuit SAN FRANCISCO , CA / ACCESSWIRE / September 25, 2019 / Hagens Berman reminds investors in Oasmia ...
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Oasmia Pharmaceutical AB (OASM) from October 23, 2015 through July 9, 2019, inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than September 27, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
NEW YORK, NY / ACCESSWIRE / September 26, 2019 / Oasmia Pharmaceutical AB (OTCPINK: OASM ) will be discussing their earnings results in their 2020 First Quarter Earnings to be held on September 26, 2019 ...
New York, New York--(Newsfile Corp. - September 25, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Oasmia Pharmaceutical AB (NASDAQ: OASM) ("Oasmia" or the "Company") of the September 27, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.If you invested in Oasmia stock or options between October 23, 2015 and July 9, 2019 and ...
LOS ANGELES, CA / ACCESSWIRE / September 26, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Oasmia Pharmaceutical AB ("Oasmia" or "the Company") (NASDAQ:OASM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 23, 2015 and July 9, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 27, 2019.
LOS ANGELES, CA / ACCESSWIRE / September 21, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Oasmia Pharmaceutical AB ("Oasmia" or "the Company") (NASDAQ:OASM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 23, 2015 and July 9, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 27, 2019.
LOS ANGELES, CA / ACCESSWIRE / September 23, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Oasmia Pharmaceutical AB ("Oasmia" or "the Company") (NASDAQ:OASM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 23, 2015 and July 9, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 27, 2019.